| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016 | 3742 | 2016 |
| Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial C Louvet, R Labianca, P Hammel, G Lledo, MG Zampino, T André, ... Journal of Clinical Oncology 23 (15), 3509-3516, 2005 | 1275 | 2005 |
| CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner F Ghiringhelli, C Ménard, M Terme, C Flament, J Taieb, N Chaput, ... The Journal of experimental medicine 202 (8), 1075-1085, 2005 | 1234 | 2005 |
| VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors T Voron, O Colussi, E Marcheteau, S Pernot, M Nizard, AL Pointet, ... Journal of Experimental Medicine 212 (2), 139-148, 2015 | 1134 | 2015 |
| Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up G Argilés, J Tabernero, R Labianca, D Hochhauser, R Salazar, T Iveson, ... Annals of Oncology 31 (10), 1291-1305, 2020 | 1089 | 2020 |
| Duration of adjuvant chemotherapy for stage III colon cancer A Grothey, AF Sobrero, AF Shields, T Yoshino, J Paul, J Taieb, ... New England Journal of Medicine 378 (13), 1177-1188, 2018 | 1046 | 2018 |
| FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis M Suker, BR Beumer, E Sadot, L Marthey, JE Faris, EA Mellon, ... The Lancet Oncology 17 (6), 801-810, 2016 | 973 | 2016 |
| Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ A Cervantes, R Adam, S Roselló, D Arnold, N Normanno, J Taïeb, ... Annals of Oncology 34 (1), 10-32, 2023 | 926 | 2023 |
| Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma … V Vilgrain, H Pereira, E Assenat, B Guiu, AD Ilonca, GP Pageaux, A Sibert, ... The Lancet Oncology 18 (12), 1624-1636, 2017 | 859 | 2017 |
| VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer M Terme, S Pernot, E Marcheteau, F Sandoval, N Benhamouda, ... Cancer research 73 (2), 539-549, 2013 | 683 | 2013 |
| A novel dendritic cell subset involved in tumor immunosurveillance J Taieb, N Chaput, C Ménard, L Apetoh, E Ullrich, M Bonmort, ... Nature medicine 12 (2), 214-219, 2006 | 542 | 2006 |
| Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction … YJ Bang, EY Ruiz, E Van Cutsem, KW Lee, L Wyrwicz, M Schenker, ... Annals of Oncology 29 (10), 2052-2060, 2018 | 521 | 2018 |
| Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Rα S Viaud, M Terme, C Flament, J Taieb, F André, S Novault, B Escudier, ... PloS one 4 (3), e4942, 2009 | 494 | 2009 |
| SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation … GA Van Hazel, V Heinemann, NK Sharma, MPN Findlay, J Ricke, ... Journal of Clinical Oncology 34 (15), 1723-1731, 2016 | 424 | 2016 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 405 | 2017 |
| Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with … E Tartour, H Pere, B Maillere, M Terme, N Merillon, J Taieb, F Sandoval, ... Cancer and Metastasis Reviews 30, 83-95, 2011 | 376 | 2011 |
| Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell–dependent antitumor effects C Borg, M Terme, J Taïeb, C Ménard, C Flament, C Robert, K Maruyama, ... The journal of clinical investigation 114 (3), 379-388, 2004 | 363 | 2004 |
| Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection N Chaput, NEC Schartz, F André, J Taïeb, S Novault, P Bonnaventure, ... The Journal of Immunology 172 (4), 2137-2146, 2004 | 358 | 2004 |
| Control of the immune response by pro-angiogenic factors T Voron, E Marcheteau, S Pernot, O Colussi, E Tartour, J Taieb, M Terme Frontiers in oncology 4, 70, 2014 | 353 | 2014 |
| Identification of CD8+ CD25+ Foxp3+ suppressive T cells in colorectal cancer tissue N Chaput, S Louafi, A Bardier, F Charlotte, JC Vaillant, F Ménégaux, ... Gut 58 (4), 520-529, 2009 | 341 | 2009 |
Pierre Laurent-PuigUniversité Paris Citéparisdescartes.fr의 이메일 확인됨
